GlycoMimetics to Present at Four Investor Conferences This Month
March 07 2018 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will
present at four investor conferences during the month of March,
including:
30th Annual ROTH
ConferenceMarch 11 – 14, 2018, The Ritz Carlton, Dana Point,
CACFO Brian Hahn will present on March 12 at 3:30 p.m. PT.
Cowen 38th Annual Health
Care ConferenceMarch 11 – 14, 2018, Copley Place Marriott,
Boston, MACEO Rachel King will present on March 14 at 9:20 a.m.
ET.
BioCentury: 25th Annual
Future Leaders in the BioTech IndustryMarch 23, 2018,
Millennium Broadway Hotel & Conference Center, New York, NYMrs.
King will present in room 311 at 2:30 p.m. ET.
Needham & Company’s 17th
Annual HealthCare ConferenceMarch 27 – 28, 2018, Westin
Grand Central Hotel, New York, NYMrs. King will present on March 27
at 8:00 a.m. ET.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271, an
E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial
as a potential treatment for AML and is currently being evaluated
in a Phase 1 clinical trial for the treatment of multiple
myeloma. The FDA granted GMI-1271 Breakthrough Therapy
designation for the treatment of adult AML patients with
relapsed/refractory disease. GlycoMimetics has also recently
initiated a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180307005331/en/
For GlycoMimetics, Inc.Investors:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024